NuVasive commenced U.S. launch of AttraX® Scaffold absorbent ceramic-collagen bone graft.
The surface of AttraX has been validated in preclinical testing to drive increased bone formation and faster fusion vs. traditional ceramic bone grafts, reportedly supporting differentiation of mesenchymal stem cells into bone-forming osteoblasts without the addition of growth factors. The device is available in strips, blocks and morsels, and complements the company’s AttraX Putty synthetic graft, launched in 2016.
NUVA’s other biologic products include Osteocel® cellular allograft and Propel™ demineralized bone matrix.
NuVasive commenced U.S. launch of AttraX® Scaffold absorbent ceramic-collagen bone graft.
The surface of AttraX has been validated in preclinical testing to drive increased bone formation and faster fusion vs. traditional ceramic bone grafts, reportedly supporting differentiation of mesenchymal stem cells into bone-forming osteoblasts without...
NuVasive commenced U.S. launch of AttraX® Scaffold absorbent ceramic-collagen bone graft.
The surface of AttraX has been validated in preclinical testing to drive increased bone formation and faster fusion vs. traditional ceramic bone grafts, reportedly supporting differentiation of mesenchymal stem cells into bone-forming osteoblasts without the addition of growth factors. The device is available in strips, blocks and morsels, and complements the company’s AttraX Putty synthetic graft, launched in 2016.
NUVA’s other biologic products include Osteocel® cellular allograft and Propel™ demineralized bone matrix.
Copy to clipboard 
